Intravenous Infusions is trading 5.66% down at GHS 0.50, with no clear company-specific announcement or fresh catalyst identified for September 25, 2026.

  • Its latest reported half-year results, published July 30, showed sales declining to GHS 4.28 million.
  • Net income improved to GHS 0.176 million from a loss previously; the results are too stale to directly explain today’s decline.